By Fineline Cube 
Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK) reported third‑quarter fiscal 2025 revenue of 3,411.2 billion yen (USD 22.17 billion), down 3.3% year‑on‑year (YOY), while net profit grew 1.2% to 422.4 billion yen (USD 2.75 billion). The company narrowed the gap between new product growth and VYVANSE generic erosion while cutting operating expenses, prompting a raised full‑year revenue forecast.
Financial Performance Summary
| Metric | Q3 FY2025 YTD | USD Equivalent | YOY Growth |
|---|---|---|---|
| Revenue | 3,411.2 billion yen | 22.17 billion | -3.3% |
| Net Profit | 422.4 billion yen | 2.75 billion | +1.2% |
| Full‑Year Forecast | 4,530.0 billion yen | 29.44 billion | Raised from 4,500.0 billion yen |
Key Business Drivers
VYVANSE Erosion Impact:
- Generic competition continues to weigh on revenue, but the gap between new product growth and VYVANSE decline is narrowing
- Operational efficiencies drove year‑on‑year reductions in operating expenses, including R&D
Growth & Launch Products:
- Newer medicines partially offset legacy headwinds, though specific product details were not disclosed in the earnings release
Profitability Improvement:
- Net profit margin expanded despite revenue decline, reflecting disciplined cost management
Outlook & Guidance
Raised Forecast:
Takeda increased its full‑year revenue projection from 4,500.0 billion yen to 4,530.0 billion yen, signaling confidence in new product momentum and cost controls despite ongoing generic pressures.
Strategic Positioning:
The company highlighted that operational efficiencies and narrowing VYVANSE impact gap position it for sustained profitability improvement through FY2025.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Takeda’s full‑year forecast and operational expectations. Actual results may differ due to competitive dynamics, regulatory changes, and market conditions.-Fineline Info & Tech